Circulating Free RNA as a Therapeutic Evaluation in Diffuse Large B-cell Lymphoma: A Case Series from the Indonesian Cancer Center

Noorwati Sutandyo, Ikhwan Rinaldi, Lyana Setiawan, Christine Sugiarto, Yuniar Harris Prayitno

Abstract


Cancer is still the leading cause of death worldwide. Despite advances in diagnosis, management with the rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) chemotherapy regimen, and careful clinical and radiologic evaluation, diffuse large B-cell lymphoma (DLBCL) still carries high recurrence in clinical practice. This case series aims to assess the potential of circulating free RNA as a biomarker for evaluating therapeutic responses in DLBCL. This case series was conducted at Dharmais National Cancer Center Hospital in Jakarta in 2020. The subjects were 13 DLBCL patients who came for treatment to our hospital in 2020. Sampling was carried out by taking peripheral blood, which was taken 7–14 days after the patient underwent the 3rd and 6th cycles of chemotherapy or before and 7–14 days following the 3rd cycle of chemotherapy. Circulating free RNA (cfRNA) was extracted and assessed. The quantity of cfRNA was subsequently examined twice as matching samples from each patient, with the following results – (1) no mutations detected; (2) mutation detected solely in the second examination; (3) mutation only detected in the first examination; and (4) changes in gene mutations and mutation types. Statistic tabulation neither showed an association between recurrency and clinical variables nor detected cfRNA from the matching samples. This case series underscores the challenges in utilizing cfRNA as a biomarker for therapeutic evaluation in DLBCL due to heterogeneity and increased mutations in post chemotherapy conditions. Further research with larger sample sizes is needed to emphasize the role of cfRNA in DLBCL disease monitoring.


Keywords


circulating free RNA; DLBCL; therapeutic evaluation; lymphoma; NGS

References


Indonesia - International Agency for Research on Cancer [Internet]. [cited 2023Jan16]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf

Bowzyk Al-Naeeb A, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ. 2018.

Intragumtornchai T, Bunworasate U, Wudhikarn K, et al. Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. Hematological Oncology. 2017;36(1):28–36.

Freedman AS, Friedberg JW. Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically-unfit [Internet]. UpToDate. [cited 2023Jan16]. Available from: https://www.uptodate.com/contents/diffuse-large-b-cell-lymphoma-dlbcl-second-or-later-relapse-or-patients-who-are-medically-unfit

Cheah CY, Hofman MS, Dickinson M, et al. Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer. 2013;109(2):312–7.

Moskowitz CH, Schöder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2010;28(11):1896–903.

Muringampurath-John D, Jaye DL, Flowers CR, et al. Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. Br J Haematol. 2012;158(5):608–614. doi:10.1111/j.1365-2141.2012.09209.x

Decruyenaere P, Offner F, Vandesompele J. Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review. Exp Hematol Oncol. 2021;10(1):13. Published 2021 Feb 16. doi:10.1186/s40164-021-00208-3

Umu SU, Langseth H, Bucher-Johannessen C, et al. A comprehensive profile of circulating RNAS in human serum. RNA Biology. 2017;15(2):242–50.

Zuo Z, Hu H, Xu Q, et al. BBCancer: An expression atlas of blood-based biomarkers in the early diagnosis of cancers. Nucleic Acids Research. 2019;

Hassan S, Shehzad A, Khan SA, Miran W, Khan S, Lee Y-S. Diagnostic and therapeutic potential of circulating-free DNA and cell-free RNA in cancer management. Biomedicines. 2022;10(8):2047.

Beck TN, Boumber YA, Aggarwal C, et al. Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer. BMC Cancer. 2019;19(1).

Kishikawa T. Circulating RNAS as new biomarkers for detecting pancreatic cancer. World Journal of Gastroenterology. 2015;21(28):8527.

Circulating cell-free RNA: A new perspective for endometrial cancer. Archives of Obstetrics and Gynaecology. 2020;1(2).

Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW. Translating RNA sequencing into clinical diagnostics: Opportunities and challenges. Nature Reviews Genetics. 2016;17(5):257–71.

El Marabti E, Younis I. The cancer spliceome: Reprograming of alternative splicing in cancer. Front Mol Biosci. 2018;5:80. Published 2018 Sep 7. doi:10.3389/fmolb.2018.00080

Ben-Aroya S, Levanon EY. A-to-I RNA editing: An overlooked source of cancer mutations. Cancer Cell. 2018;33(5):789–90. doi:10.1016/j.ccell.2018.04.006

Zaporozhchenko IA, Ponomaryova AA, Rykova EY, Laktionov PP. The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities. Expert Rev Mol Diagn. 2018;18(2):133–45. doi:10.1080/14737159.2018.1425143

Pellegrini KL, Sanda MG, Moreno CS. RNA biomarkers to facilitate the identification of aggressive prostate cancer. Molecular Aspects of Medicine. 2015;45:37–46.

Gallo A, Vukic D, Michalík D, O’Connell MA, Keegan LP. Adar RNA editing in human disease; more to it than meets the I. Human Genetics. 2017;136(9):1265–78.

Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: Approaches and considerations. Nature Reviews Genetics. 2012;13(5):358–69.

Ozsolak F, Milos PM. RNA sequencing: Advances, challenges and opportunities. Nature Reviews Genetics. 2010;12(2):87–98.

Modelska A, Quattrone A, Re A. Molecular portraits: The evolution of the concept of transcriptome-based cancer signatures. Briefings in Bioinformatics. 2015;16(6):1000–7.

Marisa L, de Reyniès A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value. PLoS Medicine. 2013;10(5).

Brodtkorb M, Lingjærde OC, Huse K, et al. Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood. 2014;123(7):1051–4.

Søkilde R, Vincent M, Møller AK, et al. Efficient identification of mirnas for classification of tumor origin. The Journal of Molecular Diagnostics. 2014;16(1):106–15.

Pease J, Kinross C. Improved RNA-seq of blood-derived RNA increases gene discovery and coverage. Nature Methods. 2013;10(7):i–ii.

Shin H, Shannon CP, Fishbane N, et al. Variation in RNA-seq transcriptome profiles of peripheral whole blood from healthy individuals with and without globin depletion. PLoS ONE. 2014;9(3).

Kaczkowski B, Tanaka Y, Kawaji H, et al. Transcriptome analysis of recurrently deregulated genes across multiple cancers identifies new pan-cancer biomarkers. Cancer Res. 2016;76(2):216–26. doi:10.1158/0008-5472.CAN-15-0484

Lymphoma kit - diagnóstica longwood [Internet]. [cited 2023May3]. Available from: https://dlongwood.com/wp-content/uploads/2019/11/archer-FusionPlex-Lymphoma_diagnostica-longwood.pdf

Sorber L, Zwaenepoel K, Jacobs J, et al. Circulating cell-free DNA and RNA analysis as liquid biopsy: Optimal centrifugation protocol. Cancers. 2019;11(4):458.

Metzenmacher M, Váraljai R, Hegedüs B, et al. Plasma next generation sequencing and droplet digital-qpcr-based quantification of circulating cell-free RNA for noninvasive early detection of cancer. Cancers. 2020;12(2):353.

Cabús L, Lagarde J, Curado J, Lizano E, Pérez-Boza J. Current challenges and best practices for cell-free long RNA biomarker discovery. Biomarker Research. 2022;10(1).

Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–90.

Norton SE, Lechner JM, Williams T, Fernando MR. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clinical Biochemistry. 2013;46(15):1561–5.

Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–48. doi:10.1038/nrclinonc.2017.14

Russo M, Misale S, Wei G, et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 2016;6(1):36-44. doi:10.1158/2159-8290.CD-15-0940

Nilsson RJ, Karachaliou N, Berenguer J, et al. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget. 2016;7(1):1066–75. doi:10.18632/oncotarget.6279

Best MG, Wesseling P, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Cancer Res. 2018;78(13):3407–12. doi:10.1158/0008-5472.CAN-18-0887

Normanno N, Cervantes A, Ciardiello F, De Luca A, Pinto C. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. Cancer Treat Rev. 2018;70:1–8. doi:10.1016/j.ctrv.2018.07.007

Ladurner M, Wieser M, Eigentler A, et al. Validation of cell-free RNA and circulating tumor cells for molecular marker analysis in metastatic prostate cancer. Biomedicines. 2021;9(8):1004.

El-Galaly TC, Villa D, Alzahrani M, et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90(11):1041–6. doi:10.1002/ajh.24169

Bobillo S, Joffe E, Lavery JA, et al. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era [published correction appears in Blood. 2022 Mar 17;139(11):1772]. Blood. 2021;137(1):39–48. doi:10.1182/blood.2020005112

Liu YZ, Luo P, Liu C, et al. Prognostic significance of LDH ratio in serum/cerebral spinal fluid of patients with primary testicular diffuse large B-cell lymphoma. Onco Targets Ther. 2019;12:10469–75. Published 2019 Dec 2. doi:10.2147/OTT.S228746

Miyashita K, Tomita N, Taguri M, et al. Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy [published online ahead of print, 2015 Aug 29]. Leuk Res. 2015;S0145-2126(15)30368–4. doi:10.1016/j.leukres.2015.08.016

Nijland M, Seitz A, Terpstra M, et al. Mutational evolution in relapsed diffuse large B-cell lymphoma. Cancers (Basel). 2018;10(11):459. Published 2018 Nov 20. doi:10.3390/cancers10110459

Morin RD, Arthur SE, Hodson DJ. Molecular profiling in diffuse large b‐cell lymphoma: Why so many types of subtypes? British Journal of Haematology. 2021;196(4):814–29.

Young RM, Phelan JD, Shaffer AL, et al. Taming the heterogeneity of aggressive lymphomas for precision therapy. Annual Review of Cancer Biology. 2019;3(1):429–55.

Lee B, Lee H, Cho J, et al. Mutational profile and clonal evolution of relapsed/refractory diffuse large B-cell lymphoma. Frontiers in Oncology. 2021;11.

Guo L, Lin P, Xiong H, Tu S, Chen G. Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2018;1869(2):85–96.

Wagner JT, Kim HJ, Johnson-Camacho KC, et al. Diurnal stability of cell-free DNA and cell-free RNA in human plasma samples. Scientific Reports. 2020;10(1).

Souza MF, Kuasne H, Barros-Filho Mde, et al. Circulating mrnas and mirnas as candidate markers for the diagnosis and prognosis of prostate cancer. PLOS ONE. 2017;12(9).


Full Text: PDF

Refbacks

  • There are currently no refbacks.